Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-05-23
1996-08-13
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514178, A61K 3156
Patent
active
055456359
ABSTRACT:
The present invention provides methods of inhibiting bone loss in humans comprising administering to a patient in need of treatment an effective amount of d-equilenin, 17.beta.-dihydroequilenin, and 17.alpha.-dihydroequilenin, and pharmaceutical formulations thereof.
REFERENCES:
patent: 4154820 (1979-05-01), Simoons
Prestwood, K. M., et al., J. Clin. Endocrinol. Metab., 79(2):366-371 (1994).
Genant H. K., et al., Obstet. Gynecol., 76(4):579-584 (1990).
Von Beck, A., et al., Wein Klin Wochenschr, 87(2):59-62 (1975).
Bhavnani, B. R., Endocrine Reviews, 9(4):396-416 (1988).
Washburn, S. A. et al., Am. J. Obstet. Gynecol., 169:(2,I):251-256 (1993).
Wronski, T. J., et al., Endocrinology, 123(2):681-686, (1988).
Bryant Henry U.
Dodge Jeffrey A.
Sato Masahiko
Yang Na N.
Boone David E.
Criares Theodore J.
Eli Lilly and Company
Sales James J.
LandOfFree
Inhibiting bone loss with equilenin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibiting bone loss with equilenin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting bone loss with equilenin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1048041